Atlas Trials

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Clinical trial NCT02514083 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02514083
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Start date
2015-12-09
Primary completion
2019-10-02
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.